24 September 2010

Cancer Treatment by Electromagnetic Fields Goes Mainstream

Before and after applying 200khz frequencies to brain cancer. Disease has stabilized.

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proceedings National Academy of Sciences, June 12, 2007 vol. 104 no. 24 10152-10157.
Author Affiliations
  • *NovoCure Limited, Matam Advanced Technology Centre, Haifa 31905, Israel;
  • Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic;
  • Rambam Medical Center, PO Box 9602, Haifa 31096, Israel;
  • §Basel University Hospitals, Hebelstrasse 32, 4031 Basel, Switzerland;
  • Centre National de la Recherche Scientifique, Laboratoire d'immunologie et Embryologie Moléculaire, Rue de la Ferollerie, 45071 Orleans, France;
  • Weizmann Institute of Science, PO Box 26, Rehovot 76100, Israel; and
  • **B. Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Technion City, Haifa 32000, Israel
  • Communicated by Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, April 5, 2007 (received for review January 15, 2007) 
We have recently shown that low intensity, intermediate frequency, electric fields inhibit by an anti-microtubule mechanism of action, cancerous cell growth in vitro. Using implanted electrodes, these fields were also shown to inhibit the growth of dermal tumors in mice. The present study extends these findings to additional cell lines [human breast carcinoma; MDA-MB-231, and human non-small-cell lung carcinoma (H1299)] and to animal tumor models (intradermal B16F1 melanoma and intracranial F-98 glioma) using external insulated electrodes. These findings led to the initiation of a pilot clinical trial of the effects of TTFields in 10 patients with recurrent glioblastoma (GBM). Median time to disease progression in these patients was 26.1 weeks and median overall survival was 62.2 weeks. These time to disease progression and OS values are more than double the reported medians of historical control patients. No device-related serious adverse events were seen after >70 months of cumulative treatment in all of the patients. The only device-related side effect seen was a mild to moderate contact dermatitis beneath the field delivering electrodes. We conclude that TTFields are a safe and effective new treatment modality which effectively slows down tumor growth in vitro, in vivo and, as demonstrated here, in human cancer patients.

Despite using frequencies that are not optimal for eliminating cancer cells and not using frequencies to eliminate Rife BX BY and Gregory cancer virus infections, significant benefit was found with long term treatment of brain cancer with an electromagnetic device designed by NovoCure. A clinical trial is well under way.

11 September 2010

EFT (Emotional Freedom Technique) in the News

View video

Fear of spiders, heights, flying, whatever? The first thing you should try is a simple process of tapping on acupuncture meridians. The reporter above had fear of spiders for 25 years and after a couple of minutes of tapping was able to hold a tarantulla and feel like it was cute and cuddly. See video ...

For most emotional problems EFT is the first option of choice as it takes only a few minutes and has no negative side effects. It it works, great! If not, try something else. (Actually, if you persist with EFT and/or get some help it will always offer some benefit.)

Significant research material is available for EFT and you can download a manual for free.

05 September 2010

Lyme Bacteria - Borrelia Burgdorferi Version 1.0

The conventional view of lyme disease is that it is caused by Borrelia burgdorferi and with a few months of antibiotics you are cured. If you believe this, I have a bridge in Brooklyn that I would like to sell you. Those who have a serious interest in this disease should read Lab 257 which thoroughly documents the many years of government violation of EPA safety standards at the weapons lab that generated this problem.

Nevertheless, this bacteria is the most immediately crippling of the lyme complex. It should be eliminated first and it only takes a few hours of frequency application. As with all lyme organisms, there needs to be repeated checkups to make sure it is completely gone for at least six months. Reinfection with lyme is now becoming increasingly common as many of the flying insects (in addition to ticks) in infested areas now carry some or all of the many hundreds of lyme organisms.

Borrelia burgdorferi is a species of Gram negativebacteria of the spirochete class of the genus Borrelia. B. burgdorferi is predominant in North America, but also exists in Europe, and is the agent of Lyme disease.

It is a zoonotic, vector-borne disease transmitted byticks and is named after the researcher Willy Burgdorfer who first isolated the bacterium in 1982. B. burgdorferi is one of the few pathogenic bacteria that can survive without iron, having replaced all of its iron-sulfur cluster enzymes with enzymes that use manganese, thus avoiding the problem many pathogenic bacteria face in acquiring iron.

B. burgdorferi infections have been linked to non-Hodgkin lymphomas.

B. burgdorferi (B31 strain) was the third microbialgenome ever sequenced, following the sequencing of both H. influenzae and M. genitalium in 1995, and contains 910,725 base pairs and 853 genes. The sequencing method used was whole genome shotgun. The sequencing project, completed and published in Nature in 1997, was conducted at The Institute for Genomic Research.

Its clinical features includes "Lyme Disease", manifesting Erythema chronicum migrans with Bull eye rash (a rash which spreads peripherally and sparing the central part), myocarditis, cardiomyopathy, arrythmias, arthritis, arthralgia, neuropathy and fascial nerve palsy.

It is common in North east, mid west and western US and is now becoming a worldwide epidemic. See recent results from Sweden published in the New England Journal of Medicine.

Frequencies for Borrelia Burgdorferi Version 1.0 are published for subscribers at http://subscribers.frequencyfoundation.com.